Endlyz Therapeutics Secures New Financing to Advance Parkinson’s Disease Drug Discovery Programs
Endlyz Therapeutics, a biotechnology company developing disease-modifying treatments for Parkinson’s disease and other neurodegenerative disorders, has secured new financing to advance its pipeline of small-molecule therapeutics targeting lysosomal dysfunction. The company’s investor syndicate includes SV Health Investors’ Dementia Discovery Fund, Oxford Science Enterprises, AbbVie Ventures, Parkinson’s UK, Centre for Drug Design and Discovery, and Oxford University Innovation. The financing will support the company’s efforts to advance its ATP13A2 and ATP10B therapeutic programs aimed at restoring cellular waste-clearing functions linked to Parkinson’s disease.
Founded in 2021 by SV Health Investors’ Dementia Discovery Fund, Endlyz Therapeutics is focused on developing therapies that address the underlying biological mechanisms driving neurodegeneration rather than only treating symptoms. The company is developing small-molecule modulators of lysosomal transporters ATP13A2 and ATP10B, which play important roles in maintaining neuronal health and are associated with Parkinson’s disease and other neurological conditions.
Endlyz emerged from stealth in 2025 with a portfolio of programs designed to restore endo-lysosomal function, a cellular process responsible for managing waste and maintaining healthy cell function. The company believes dysfunction in this system contributes to the progression of neurodegenerative diseases and represents an opportunity for disease-modifying treatments.
The company’s lead research programs focus on ATP13A2, a lysosomal transporter encoded by the PARK9 gene that has been genetically linked to Parkinson’s disease, and ATP10B, a lipid transporter associated with Parkinson’s risk. Endlyz is developing small-molecule potentiators designed to increase the activity of these targets and potentially restore normal cellular processes.
The latest financing builds on earlier support from investors and research organizations backing Endlyz’s approach to Parkinson’s disease treatment. The company’s investor base includes SV Health Investors’ Dementia Discovery Fund, which helped establish Endlyz, along with Oxford Science Enterprises and AbbVie Ventures. These investors have supported the company’s development of therapies targeting the biological causes of neurodegeneration.
Parkinson’s UK and the Centre for Drug Design and Discovery have also supported Endlyz’s work. CD3, a collaboration between KU Leuven and other partners, provides expertise and resources for translating academic discoveries into drug development programs. Endlyz has built collaborations with researchers at KU Leuven and the University of Oxford to advance its discovery efforts.
In addition to equity investment, Endlyz received a $2.2 million grant from the Michael J. Fox Foundation for Parkinson’s Research through its Parkinson’s Disease Therapeutics Pipeline Program. The grant is supporting the discovery of translational biomarkers that can help connect preclinical research findings with future clinical development.
The company’s scientific efforts are supported by collaborations with leading academic researchers. Professor Peter Vangheluwe of KU Leuven joined Endlyz as a scientific co-founder, contributing expertise in lysosomal transporters and drug discovery. Endlyz also works with Professor Richard Wade-Martins and Professor John Davis from the University of Oxford, who provide expertise in Parkinson’s disease mechanisms and translational research models.
The funding comes at a time when biotechnology companies are increasingly focused on developing treatments that modify disease progression in neurodegenerative disorders. Parkinson’s disease affects millions of people worldwide, and current therapies primarily address symptoms without stopping or reversing the underlying disease process.
Endlyz aims to create therapies that intervene earlier in disease biology by targeting cellular pathways involved in neuronal survival. The company’s approach is centered on improving lysosomal function, which plays a critical role in clearing damaged proteins and maintaining healthy cells.
The company plans to use the financing to continue advancing its lead programs, conduct additional research, and prepare its therapies for future stages of development. Endlyz has indicated that it intends to move its lead programs through additional preclinical development and eventually toward clinical testing.
The company has also expanded its scientific network through collaborations involving artificial intelligence and advanced drug discovery technologies. Its partnership with KU Leuven and related research efforts aim to accelerate identification and evaluation of potential drug candidates.
With support from a group of healthcare-focused investors and research organizations, Endlyz Therapeutics is working to establish a new approach to treating Parkinson’s disease by targeting the cellular mechanisms believed to contribute to neurodegeneration. The company’s ongoing development programs reflect a broader shift in biotechnology toward therapies designed to address the root causes of complex neurological diseases rather than simply managing their symptoms.
